Overview of Sobi's Third Quarter Report
Swedish Orphan Biovitrum AB (publ) (Sobi) has released an impressive report detailing its performance for the third quarter of 2024, highlighting remarkable growth and a robust pipeline of prospects. The company’s total revenue saw a rise of 33 percent, which is equivalent to 39 percent when calculated at constant exchange rates (CER), reaching an impressive SEK 6,894 million compared to SEK 5,168 million.
Haematology and Immunology Revenue Surge
Growth in Haematology
Within the haematology segment, Sobi reported an 18 percent increase at CER, bringing the revenue to SEK 4,000 million, primarily driven by strong sales of Doptelet, which saw sales of SEK 1,039 million up from SEK 650 million. Additionally, products like Aspaveli/Empaveli generated SEK 270 million in sales while the recently launched Altuvoct contributed SEK 129 million.
Immunology Performance
The immunology segment exhibited even more significant growth, with a 96 percent increase at CER, totaling SEK 2,583 million. This was largely fueled by a remarkable royalty of SEK 1,478 million from Beyfortus, alongside sales from Kineret that achieved SEK 699 million up from SEK 600 million.
Strategic Portfolio Growth
Sobi's medicines within the strategic portfolio grew by an incredible 113 percent at CER, amounting to SEK 3,830 million compared to SEK 1,924 million. This strong performance showcases the growing trust in Sobi's innovative treatment solutions across various medical fields.
Financial Highlights
The adjusted EBITA margin for the quarter stood at 43 percent, a substantial increase from 30 percent in the previous year, driven by improved operational efficiencies. Sobi's EBITA reached SEK 2,923 million with a margin of 42 percent, compared to last year's margin of 28 percent. The net EBIT recorded was SEK 2,038 million, significantly up from SEK 547 million.
Additionally, earnings per share (EPS) before dilution increased to SEK 4.27 from 0.30. Adjusted EPS before dilution grew to SEK 4.36 compared to 0.54 from the previous year. Cash flow from operating activities was also healthy, totaling SEK 1,201 million compared to SEK 1,058 million last year.
Future Outlook
Looking ahead, Sobi anticipates revenue growth in the mid-teens percentage range at CER, an upgrade from earlier expectations of low double-digit growth. The adjusted EBITA margin forecast remains unchanged, expected to be in the mid-thirties percentage of the revenue.
Upcoming Events
Investors, analysts, and media professionals are invited to a conference call on the reporting day where the results will be presented, followed by a Q&A session. Participants can join the call at 14:00 CEST, 13:00 BST, and 08:00 EDT. Detailed logistical information and access links for the presentation will be provided on Sobi's website.
About Sobi
Sobi is dedicated to transforming the lives of individuals suffering from rare and debilitating diseases through specialized biopharmaceuticals. The company provides reliable access to innovative medicines in the fields of haematology, immunology, and specialty care, employing around 1,800 professionals worldwide. Sobi generated revenues of SEK 22.1 billion in 2023, and its shares are traded on Nasdaq Stockholm (STO:SOBI). For further information about Sobi's initiatives and products, please visit their official website.
Frequently Asked Questions
What were Sobi's key financial results in Q3 2024?
In Q3 2024, Sobi reported a total revenue of SEK 6,894 million and a significant increase in both haematology and immunology revenues.
What is the outlook for Sobi in 2024?
Sobi anticipates mid-teens revenue growth at constant exchange rates for 2024 while maintaining its target for the adjusted EBITA margin.
What are the growth areas for Sobi?
Haematology and immunology are key growth areas, with products like Doptelet and Beyfortus driving significant revenue increases.
How is Sobi enhancing its market position?
Sobi is focusing on expanding its strategic portfolio and strengthening sales through ongoing innovation and market adaptability.
What can investors expect from Sobi moving forward?
Investors can expect a continued emphasis on growth, innovation, and a strong financial performance supporting Sobi's mission to transform patient care.
